Bacterial Enzymes as Targets for Drug Discovery

Meeting the Challenges of Antibiotic Resistance

Punit Kaur, Priyanka Sharma (Herausgeber)

Buch | Softcover

400 Seiten

2024
Academic Press Inc (Verlag)
978-0-443-22222-1 (ISBN)

Noch nicht erschienen (ca. November 2024)
Versandkostenfrei
Auch auf Rechnung

Artikel merken

Bacterial Enzymes as Targets for Drug Discovery: Meeting the Challenges of Antibiotic Resistance addresses the gap between medical microbiology, structural biology, and genomic science in the development of new antibacterial drug development. This book consolidates detailed profiling of bacterial target enzyme families for the drug discovery process and methodologies for use and validation of the potential drug targets. The content covers the foundations of antibiotic drug discovery process and focuses on bacterial enzymes as drug targets, building a bridge between microbiology, structural biology, and genomic science. This is the ideal reference for antibiotic drug discovery researchers in the pharma industry and academia. Biochemists, microbiologists, and medicinal chemists will also benefit from this books’ content.

Dr. Kaur’s specialties include Bioinformatics, Structural Biology, X-ray Crystallography, and Rational Structure-Based Drug Design. Her research focuses on clinically relevant bacterial pathogens where a multidisciplinary approach is adopted to understand the antibacterial resistance mechanisms and design of novel inhibitory molecules. She has published more than 240 original publications, reviews and chapters in the field of bioinformatics, biophysical enzymatic activity and structural biology. Dr. Priyanka Sharma is a postdoctoral student with the biomedical Informatics department at the ICMR. Her work focuses on the field of computational biology involving structural bioinformatics and genomics of bacterial pathogens. She has published widely in the field of clinical bacteriology and is the author of over 30 research papers, reviews and chapters. She has work experience in field of antimicrobial resistance due to enzymatic mutations.

Part I Primer of antibiotic discovery process
1. Antibacterial drug discovery: An introduction
2. Druggability of a target site
3. Dual inhibition as a novel strategy for antibiotic discovery
4. Conserved enzymes across the bacterial pathogens serves as great drug targets
5. Validation of drug targets using molecular methodologies
6. Selection of Enzymatic activity assays for validation of inhibitory potential
7. Computational tools to identify potential drug targets in bacteria
8. Antimicrobial drug resistance and bypassing strategies

Part II Bacterial enzyme as drug targets
9. Strategic identification of novel enzymes as antibacterial drug targets
10. Inhibiting the replication by targeting topoisomerases
11. Aminoglycoside modifying Enzymes (AMEs)
12. Role of beta lactamases in antibiotic drug discovery
13. Combining efflux pump inhibitory agents for broad spectrum antibacterial activity
14. Ribosomal binding antibacterial agents
15. DNA dependent RNA polymerase as an attractive drug target
16. Polymyxins and their role as next generation inhibitory compounds
17. Arresting the peptidoglycan synthesis to kill the bacteria
18. Bacterial Proteases
19. Targeting lipase enzyme for drug discovery
20. Bacteriophage mechanisms for identification of target enzymes
21. Role of regulatory RNAs as antibacterial drug targets
22. Pathogen specific antibiotic discovery
23. Drug Repurposing: Tackling the antibiotic resistance with existing therapeutics

Erscheint lt. Verlag	29.11.2024
Reihe/Serie	Foundations and Frontiers in Enzymology
Verlagsort	San Diego
Sprache	englisch
Maße	191 x 235 mm
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
ISBN-10	0-443-22222-3 / 0443222223
ISBN-13	978-0-443-22222-1 / 9780443222221
Zustand	Neuware